<html><style> .textDiv { width: 900px; border: 25px solid #58D3F7; padding: 25px; margin: 25px; font-family: 'Arial', Times, serif; font-size: 16px; text-align: justify;} .title { margin: 50px 50px 50px 25px; font-family: 'Arial', Times, serif; font-size: 40px; font-weight: bold; color:  #58D3F7; text-align: left;} </style><head></head><body><div class='title'>Uncertainty_conditionality</div><div class='textDiv'>IPO Quiet Period Expiration: Invitae Corporation - Invitae (NYSE:NVTA) | Seeking Alpha The 25-day quiet period on NVTA ends 3.9.2015, allowing its IPO underwriters (JPM, Cowen & Co., Leerink) to publish reports and recommendations on 3.10.NVTA is a company focused on bringing comprehensive genetic information into mainstream healthcare.Studies show a correlation between the quality and reputation of a firm’s underwriters and above-market returns at the expiration of many firms’ quiet periods.Investors who want to buy into NVTA may wish to take advantage of the strong opportunity presented by the upcoming quiet period expiration.We suggest buying days in advance.The 25-day quiet period on Invitae Corporation (NYSE: NVTA ) will come to an end March 9, 2015, allowing the firm's IPO underwriters to publish reports and recommendations of Invitae, a company focused on bringing comprehensive genetic information into mainstream healthcare, on March 10.A quiet period , according to SEC guidelines, is a period of time, usually 25 days, during which underwriters are barred from releasing analyses on a firm they just underwrote to help ensure a fair and stable early market for the new securities.Invitae Corporation's IPO was priced at $16, higher than the expected price range of $13 to $15.The stock opened at $17.50 and closed at $17.05 on its first day of trading.After reaching a high of $21.63 on February 18, the share price has declined slightly to $18.27 (3.5.2015 close).Invitae Corporation focuses on bringing comprehensive genetic data into the mainstream medical field in order to improve the quality of healthcare.The company processes DNA samples, analyzes the information, and produces corresponding test reports through its software and informatics capabilities and laboratory methods.Invitae can test for variations of more than 200 genes although it focuses mostly on cancer, pediatrics, neurology, hematology and cardiology.In addition, Invitae offers solutions that facilitate the sharing of genetic data with an application called the Invitae Family History Tool, which tracks family genetic history, and Clinvitae, a Web application that gives physicians and patients the ability to obtain additional genetic data by examining individual genes and variants.The company has a multi-disciplinary team of over 160 employees, including lab automation specialists, bioinformaticians, clinical and medical geneticists, genetic counselors and software engineers, among others.Invitae operates in the United States, Israel, Canada and other countries.Formerly known as Locus Development Corporation, the organization changed its name to Invitae Corporation in 2012.Company headquarters are in San Francisco, California.The genetic testing and molecular diagnostics industry is a $5 billion market in the United States, and genetic testing represents 60 percent of that revenue.Thus, many companies operate in the field of genetic testing, including Quest Diagnostics, Laboratory Corporation of America, GeneDX, Ambry Genetics and Myriad Genetics.NVTA has a notable management team which could help give it an edge over its peers.Co-founder and CEO Randy Scott was formerly CEO of Genomic Health from 2000 to 2009 and its executive chairman until 2012.Prior to Genomic Health, he held senior positions at Incyte.Dr. Scott holds a Bachelor of Science in chemistry from Emporia State University and a doctorate in biochemistry from the University of Kansas.CFO and Chief Counsel Lee Bendekgey has held positions across the finance, administrative and legal disciplines for companies such as Incyte, DNAnexus, and Nuvelo.He holds a B.A. from Kalamazoo College and he earned his law degree from Stanford Law School.NVTA's IPO underwriters will seek to capitalize on the stock's recent growth through the release of positive reports beginning with the conclusion of the quiet period.These underwriters include JPMorgan, Cowen & Co. and Leerink Partners.Studies show a correlation between the quality and reputation of a firm's underwriters and above-market returns at the expiration of many firms' quiet periods.We have done our own research and found similar results, particularly in the days (-5,+2) and (-11,0) around the expiration day (0).Investors who want to buy into Invitae Corporation may wish to take advantage of the strong buying opportunity presented by the upcoming quiet period expiration.The fact of it being backed by very powerful underwriters, combined with a solid IPO and early market performance, bode well for future gains.Source: IPO Quiet Period Expiration: Invitae Corporation Disclosure: The author is long NVTA.(More...)The author wrote this article themselves, and it expresses their own opinions.The author is not receiving compensation for it (other than from Seeking Alpha).The author has no business relationship with any company whose stock is mentioned in this article.We only use your contact details to reply to your request for more information.We do not sell the personal contact data you submit to anyone else.Thank you for your interest in Seeking Alpha PRO We look forward to contacting you shortly for a conversation.Our PRO subscription service was created for fund managers, and the cost of the product is prohibitive for most individual investors.PRO Alerts is our flagship product for individual investors who want to be faster and smarter about their stocks.To learn more about it, click here.<span style='background-color: #77ff33'>If you are an investment professional with over $1M AUM and received this message in error, click here and you will be contacted shortly.</span>We look forward to contacting you when we have an individual investor product ready!</div></body></html>